Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2011

View Archived Issues

Phase II data suggest fluoxetine improves motor recovery after ischemic stroke

Merck & Co. patents novel gamma-secretase modulators

Profectus BioSciences divulges new NF-kappa-B inhibitors

GSK discovers new lysophospholipid S1P1 receptor agonists

Vertex Pharma outlines its objectives for 2011

XL-184 receives FDA orphan drug status and is assigned generic name cabozantinib

Phase IIb trial evaluates budesonide as chemopreventive therapy in subjects with lung nodules

Cannabinoid CB1/CB2 receptors show promise as targets in NSCLC

PET ligand [11C]-RO-5013853 shows promise to evaluate Gly-T1 inhibitors

FDA accepts NDA for extended-release Janumet for review

Phase I ViaDerm-Calcitonin trial meets primary and secondary endpoints

Mithridion secures funding for drug development program

GSK-1605786 advances in phase III trial in Crohn's disease

Lilly presents new inhibitors of hedgehog signaling

FP-1097 is effective in phase II trial in female incontinence and overactive bladder

FDA accepts SmartRelief-Sumatriptan NDA for filing

Cephalon and Mesoblast report interim phase II data on Revascor

New histamine H3 receptor antagonists and/or inverse agonists discovered

Merck Serono claims new lysophospholipid S1P1 receptor agonists

FDA advisory committee recommends non-approval of Lilly's liprotamase NDA for EPI

Pfizer initiates rolling NDA submission for crizotinib for NSCLC

Enzon begins phase I study of EZN-4176 in castration-resistant prostate cancer

Daiichi Sankyo and ArQule initiate phase III trial of ARQ-197 in NSCLC

Shire reports study data on Vyvanse in excessive daytime sleepiness

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...